Journal of Visualized Experiments

Real-time In vitro Monitoring of Odorant Receptor Activation by an Odorant in the Vapor Phase

--Manuscript Draft--

Article Type:	Invited Methods Article - JoVE Produced Video
Manuscript Number:	JoVE59446R1
Full Title:	Real-time In vitro Monitoring of Odorant Receptor Activation by an Odorant in the Vapor Phase
Keywords:	Vapor stimulation; odorant receptors; real-time activation; odorant molecules; combinatorial code; functional assay
Corresponding Author:	Hiro Matsunami UNITED STATES
Corresponding Author's Institution:	
Corresponding Author E-Mail:	hiroaki.matsunami@duke.edu
Order of Authors:	Claire A. de March
	Yosuke Fukutani
	Aashutosh Vihani
	Hitoshi Kida
	Hiroaki Matsunami
Additional Information:	
Question	**Response**
Please indicate whether this article will be Standard Access or Open Access.	Standard Access (US$2,400)
Please indicate the **city, state/province, and country** where this article will be **filmed**. Please do not use abbreviations.	Durham, North Carolina, United States of America

TITLE:

Real-time In vitro Monitoring of Odorant Receptor Activation by an Odorant in the Vapor Phase

AUTHORS AND AFFILIATIONS

Claire A. de March[1], Yosuke Fukutani[1,2], Aashutosh Vihani[1,3], Hitoshi Kida[1,4], Hiroaki Matsunami[1,3,5,6]

[1]Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC, USA
[2]Department of Biotechnology and Life Science, Tokyo University of Agriculture and Technology, Tokyo, Japan
[3]Department of Neurobiology, Duke University Medical Center, Durham, NC, USA
[4]Department of Mechanical Systems, Engineering, Tokyo University of Agriculture and Technology, Tokyo, Japan
[5]Institute of Global Innovation Research, Tokyo University of Agriculture and Technology, Tokyo, Japan
[6]Duke Institute for Brain Sciences, Duke University, Durham, NC, USA

Email Addresses:
Claire A. de March claire.de.march@duke.edu
Yosuke Fukutani fukutani@cc.tuat.ac.jp
Aashutosh Vihani aashutosh.vihani@duke.edu
Hitoshi Kida kidahitoshi1028@gmail.com
Hiroaki Matsunami hiroaki.matsuami@duke.edu

Corresponding authors:
Claire A. de March
Hiroaki Matsunami

KEYWORDS:
vapor stimulation, odorant receptors, real-time activation, odorant molecules, combinatorial code, functional assay

SHORT ABSTRACT:
Physiologically, odorant receptors are activated by odorant molecules inhaled in the vapor phase. However, most in vitro systems utilize liquid phase odorant stimulation. Here, we present a method that allows real-time in vitro monitoring of odorant receptor activation upon odorant stimulation in vapor phase.

LONG ABSTRACT:
Olfactory perception begins with the interaction of odorants with odorant receptors (OR) expressed by olfactory sensory neurons (OSN). Odor recognition follows a combinatorial coding scheme, where one OR can be activated by a set of odorants and one odorant can activate a combination of ORs. Through such combinatorial coding, organisms can detect and discriminate

between a myriad of volatile odor molecules. Thus, an odor at a given concentration can be described by an activation pattern of ORs, which is specific to each odor. In that sense, cracking the mechanisms that the brain uses to perceive odor requires the understanding odorant-OR interactions. This is why the olfaction community is committed to "de-orphanize" these receptors. Conventional in vitro systems used to identify odorant-OR interactions have utilized incubating cell media with odorant, which is distinct from the natural detection of odors via vapor odorants dissolution into nasal mucosa before interacting with ORs. Here, we describe a new method that allows for real-time monitoring of OR activation via vapor-phase odorants. Our method relies on measuring cAMP release by luminescence using the Glosensor assay. It bridges current gaps between in vivo and in vitro approaches and provides a basis for a biomimetic volatile chemical sensor.

INTRODUCTION:

The sense of smell allows terrestrial animals to interact with their volatile chemical environment to drive behaviors and emotions. Fundamentally, the odor detection process begins with the very first interaction of odorant molecules with the olfactory system, at the level of odorant receptors (ORs)[1]. In mammals, ORs are individually expressed in olfactory sensory neurons (OSNs) located in the olfactory epithelium[2]. They belong to the G-protein coupled receptor (GPCR) family and more precisely to the rhodopsin-like sub-family (also called class A). ORs couple with the stimulatory G protein G_{olf} whose activation leads to cAMP production followed by the opening of cyclic nucleotide gated channels and the generation of action potentials. It is accepted that an odor percept relies on a specific pattern of activated ORs[3,4] and therefore odor recognition follows a combinatorial coding scheme, where one OR can be activated by a set of odorants and one odorant can activate a combination of ORs. And through such combinatorial coding, it is postulated that organisms can detect and discriminate between a myriad of volatile odor molecules. One of the keys to understanding how odors are perceived is to understand how and which ORs are activated by a given odor.

In an attempt to elucidate odorant-OR interactions, in vitro functional assays have played an essential role. The identification of agonist odorous ligands for orphan ORs (OR de-orphanization) has been a very active field for the past twenty years, through the use of various in vitro, ex vivo and in vivo functional assays[5-17].

In vitro assay systems are best suited for the detailed functional characterization of ORs, including identifying the functional domains and critical residues of ORs, as well as potential engineering applications. However, further development of valuable in vitro systems for ORs has been a challenge, in part due to difficulty with culturing OSNs and functional expression of ORs in heterologous cells. The first challenge had been to establish protocols that allowed for the cell surface expression of functional ORs in the mapping of odorant-OR interactions. A number of independent groups have utilized various approaches[5-12,14,18-20]. One of the earliest achievements was made by Krautwurst et al. in tagged the N-terminus of ORs with a shortened sequence of rhodopsin (Rho-tag) and observed an improved surface expression in human embryonic kidney (HEK) cells[13]. Variations made to the tag attached to the OR sequence is still a path explored for improving OR expression and functionality[19,21]. Saito et al. then identified receptor-transporting

protein 1 (RTP1) and RTP2 which facilitate OR trafficking.[22] A shorter version of RTP1, called RTP1S, has also been shown to be even more effective than the original protein[23]. The development of a cell line (Hana3A) which stably expresses G_{olf}, REEP1, RTP1, and RTP2 [24], coupled with the use of cyclic adenosine monophosphate (cAMP) reporters has enabled identification of odorant-OR interactions. The mechanism by which the RTP family of proteins promotes cell surface expression of ORs remains to be determined.

One caveat of these established methods is that they rely on odorant stimulation in liquid phase, meaning that odorants are pre-dissolved into a stimulation medium and stimulate cells by replacing the medium. This is very distinct from the physiological conditions where odorant molecules reach the olfactory epithelium in vapor phase and activate ORs by dissolution into the nasal mucosa. To more closely resemble physiologically relevant stimulus exposure, Sanz et al.[20] proposed an assay based on vapor stimulation by applying a drop of odorant solution to hang beneath the inner face of a plastic film placed on the top of cell wells. They recorded the calcium responses by monitoring fluorescence intensity. This method was the first to use air-phase odorant stimulation, but it did not allow a large screening of OR activation.

Here, we developed a new method that enables real-time monitoring of in vitro OR activation via vapor phase odorant stimulation by the Glosensor assay (**Figure 1**). This assay has been used previously in the context of liquid odorant stimulation[18,19,25-31]. The monitoring chamber of the luminometer is first equilibrated with vaporized odorant prior to plate reading (**Figure 1A**). Odorant molecules are then solvated into the buffer, bathing Hana3A cells expressing the OR of interest, RTP1S and the Glosensor proteins (**Figure 1B**). If the odorant is an agonist of the OR, the OR will switch to an activated conformation and bind the G_{olf}, activating the adenylyl cyclase (AC), and ultimately cause cAMP levels to rise. This rising cAMP will bind to and activate the Glosensor protein to generate luminescence catalyzing luciferin. This luminescence is then recorded by the luminometer and enables OR activation monitoring. This method is of high interest in the context of OR deorphanization as it brings in vitro systems closer to the natural perception of odors.

PROTOCOL:

1. Hana3A cells culture

1.1. Prepare M10 (Minimum Essential Medium (MEM) plus 10 % v/v fetal bovine serum (FBS)) and M10PSF (M10 plus 100 µg/mL penicillin-streptomycin and 1.25 µg/mL amphotericin B).

1.2. Culture the cells in 10 mL of M10PSF in a 100 mm cell culture dish in an incubator set at 37 °C and 5% carbon dioxide (CO_2).

1.3. Divide the cells every 2 days at a 20% ratio: when 100% confluence of cells (approximately 1.1 x 10^7 cells) is observed under a phase-contrast microscope, aspire the media and wash the cells gently with 10 mL of phosphate-buffered saline (PBS).

1.4. Aspirate PBS and add 3 mL of 0.05% trypsin-ethylene diamine tetraacetic acid (EDTA, 0.48

mM). Let act for approximately 1 min, until the cells dissociate from the plate.

1.5. Add 5 mL of M10 to inactivate the trypsin and eventually detach the cells still attached to the plate by pipetting up and down.

1.6. Transfer the volume (8 mL) to a 15 mL tube and centrifuge at 200 x *g* for 5 min. Aspirate the supernatant and resuspend the cells into 5 mL of M10PSF by pipetting up and down to break any cell mass. Avoid creating bubbles in the tube.

1.7. Transfer 1 mL of the resuspended cells solution in a new 100 mm cell culture dish and add 9 mL of fresh M10PSF. Incubate at 37 °C and 5% CO_2.

2. Preparation of the cells for transfection

2.1. Evaluate the confluence, or the number of cells, by observing them under a phase-contrast microscope. At least 10% confluence (approximately 1.1 x 10^6 cells) is needed for one plate.

2.2. Aspirate the media and wash the cells gently with 10 mL of PBS. Aspirate PBS and add 3 mL of EDTA. Let act for approximately 1 min at room temperature, until the cells dissociate from the plate.

2.3. Add 5 mL of M10 to inactivate the trypsin and eventually detach the cells still attached to the plate by pipetting up and down. Transfer the volume (8 mL) to a 15 mL tube and centrifuge at 200 x *g* for 5 min.

2.4. Aspirate the supernatant and resuspend the cells into 5 mL of M10PSF by pipetting up and down to break any cell mass. Avoid creating bubbles in the tube.

2.5. Depending on the number of plates to be transfected, transfer an appropriate amount of cells in a reservoir with the proper corresponding volume of M10PSF. One 96-well plate should be plated with 1/10 of a 100% confluent 100 mm dish (approximately 1.1 x 10^6 cells) diluted in M10PSF to reach a total volume of 6 mL. For one 96-well plate starting with a 100% confluence 100 mm dish, add 500 µL from the 5 mL of resuspended cells to 5.5 mL of fresh M10PSF. Mix the cells and M10PSF without generating air bubbles.

2.6. Pipette 50 µL of the suspended cells into each well of the 96-well plate using a multichannel pipette. Incubate overnight at 37 °C and 5 % CO_2.

3. Plasmid transfection

3.1. Observe the 96-well plate under a phase-contrast microscope to assure a cell confluence between 30% and 50%.

3.2. Prepare a first transfection mix that contains the plasmids common to the entire plate (RTP1S, OR and Glosensor protein, see **Table of Materials**) following the volumes in **Table 1**. Notice that the quantity of Rho-tagged OR should be divided by the number of ORs if several ORs.

NOTE: We strongly advice to add an empty vector negative control (here Rho-pCI) and any positive control (OR known to respond to the tested odorant) to the experiment plan.

3.3. Prepare a second transfection mix containing 500 µL of MEM and 20 µL of Lipofectamine 2000 reagent (valid for one 96-well plate, see **Table of Materials**). Add the second mix to the first one, and gently mix by pipetting up and down and incubate for 15 min at room temperature. Add 5 mL of M10 and mix gently.

3.4. Replace the M10PSF in the previously platted 96-well plate by 50 µL of the final transfection media. Incubate in an incubator set to 37 °C and 5% CO_2 and vacuum the chamber of the luminometer overnight following the procedure described in step 6.

4. Substrate incubation

4.1. Observe the 96-well plate under a phase-contrast microscope to assure a cell confluence between 60% and 100%. Prepare a stimulation solution of Hank's Balanced Salt Solution (HBSS) containing 10 mM of hydroxyethyl piperazineethanesulfonic acid (HEPES) and 5 mM of D-glucose.

4.2. Dilute 75 µL of the cAMP reagent (see **Table of Materials)** solution to 2.75 mL of the stimulation solution. Remove the transfection medium from the 96-well plate and wash the cells by adding 50 µL of fresh stimulation solution to each well.

4.3. Remove the stimulation solution and add 25 µL of cAMP reagent solution prepared in step 4.2 to each well. Incubate the 96-well plate at room temperature in a dark and odor-free environment (for example, a clean empty drawer far away from chemicals or any odorant source) for 2 h.

5. Odorant stimulation

5.1. First, equilibrate the luminometer chamber with volatile odorant molecules. Dilute the odorant to the desired concentration in 10 mL of mineral oil (**Figure 2A**). Before the end of the cAMP reagent incubation time, add 25 µL of the odorant solution in a new 96-well plate (not the one containing the cells). Incubate this odorant plate at room temperature in the luminometer chamber for 5 min (**Figure 2B**) (no luminometer recording is required here).

5.2. Set the luminometer to record the luminescence with 0 s of delay during 20 cycles of plate measurement of 90 s with 0.7 s of interval between cycles.

5.3. Right before reading the plate, remove the odorant plate from the chamber. Add 25 µL of odorant between the wells of the 96-well plate containing the cells (do not add the odorant in

the wells containing the cells) and quickly start the luminescence measurement of all wells for 20 cycles within 30 min (**Figure 2C**).

6. Removal of remaining odorant inside the luminometer

6.1. Open the door of the luminometer. Insert the tube connected to the vacuum pump.

6.2. Vacuum odorants in the reading chamber extensively (at least 2 h, preferably overnight) between two odorants to avoid cross contamination of odor volatiles from one experiment to another. Replace with fresh air by sending compressed air during 5 min before incubating the next odorant.

7. Data analysis

7.1. Export the data from the luminometer software.

7.2. Average the replicates of the same OR for each recording time. Calculate the normalized OR response to any eventual control (e.g., Empty vector, **Figure 3A** and representative results section) by dividing the control averaged value to the OR averaged value at each recording time (**Figure 3B** and representative results section).

7.3. Normalize the each OR response to their basal activity by dividing the averaged OR response at 0 s to each recording time response (See **Figure 3C** and representative results section).

7.4. Ccalculate the area under the curve of each OR to obtain a single OR response value. To do so, sum all the luminescence values of each recording time for each OR.

REPRESENTATIVE RESULTS:

We screened the response of three mouse ORs, Olfr746, Olfr124 and Olfr1093 using cinnamaldehyde vapor stimulation (**Figure 3**). Simultaneously, we used an empty vector control (Rho-pCI) to assure that the odorant-induced activities of the tested ORs were specific (**Figure 3A**). The real-time activation of the ORs upon vapor odorant stimulus was monitored over 20 measurement cycles. The data for each well were first normalized to the empty vector control averaged value for each cycle (**Figure 3B**). It is important to note that ORs can show variable levels of basal activity in this assay in an OR-dependent manner and it can be important to also normalize their response to this parameter (**Figure 3C**). The average value of an OR can be divided by its response at t = 0 s, allowing to compare between ORs. Single activation values for each OR can also be computed by calculating the area under the curve (AUC) for each OR by summing all measurement cycle values (**Figure 3D**).

Additionally, dose-dependent responses can be measured using this method using increasing odorant doses. We present the response of Olfr1377 to acetophenone stimulation recorded following the same procedure (**Figure 4**). Acetophenone volatility can be evaluated by its vapor

pressure, which is equal to 0.44 mm Hg at 25 °C. At a given temperature, an odorant possessing a higher vapor pressure is more volatile than an odorant with a lower vapor pressure. Acetophenone is, in consequence, a moderately volatile odorant and is exposed to the cell pure and diluted at 10^{-2}, 10^{-4}, 10^{-6} and 10^{-8}. Only the three higher concentrations (pure, 10^{-2} and 10^{-4}) are able to activate Olfr1377 (**Figure 4A**). We can also notice that the pure compound stimulation shows a tendency to decrease the OR response during time, likely due to cell toxicity, as it has been shown for eugenol in a recent publication[32]. Nevertheless, we can observe a typical dose dependency behavior of Olfr1377 (**Figure 4B**), showing that this method can also be used to determine the EC50 of OR to volatile compound.

Note that when dose-dependent experiments are performed, we do not vacuum clean the luminometer chamber. However, experiments are always performed from low to high, increasing odorant doses to minimize contaminations. Further, since the real concentration of odorant molecules in the cell media is not known, the EC50s obtained by this method are not necessarily comparable to those obtained by liquid stimulation. The EC50 values determined by our method take into account the odorant volatility, the kinetics of odorant dissolution into the medium, the odorant's solubility, and the affinity between the odorant and the OR, which are closer to the natural perception of odor. For our example of Olfr1377 stimulation by acetophenone, the EC50 value from our vapor dose-response is 161 µM (0.001874 %), which is around 50 fold higher than the liquid stimulation (3.28 µM from Saito et al.[6]). This difference between liquid and vapor stimulations was also reported by Sanz et al.[20] in their vapor stimulation assay where vapor stimulation gave 100 to 1000 fold lower EC50 values than the liquid stimulation.

FIGURE AND TABLE LEGENDS:

Figure 1: Principle of real-time monitoring of odorant receptor activation by vapored odorant. (A) The 96-well plate is placed into the already equilibrated with odor (violet cloud) luminometer chamber. **(B)** Vaporized odorant molecules (violet) at the surface of the cell media buffer dissolve into it to reach the OR cavity, at the Hana3A cell membrane surface. The accessory protein RTP1S (gray) is transfected as well, to favor the cell surface expression of the OR. If the odorant molecule is an OR agonist, the OR will switch to an activated state and bind the G_{olf}, triggering the activation of adenylyl cyclase (AC) and the production of cyclic AMP (cAMP; green). The Glosensor protein (luciferase) possesses a binding site for cAMP that, once bound, allows the protein to bind its ligand, the luciferin (yellow). The final complex Glosensor protein/luciferin/cAMP produces the luminescence that is recorded to monitor the OR activation.

Figure 2: Schematic protocols for real-time monitoring of odorant receptor activation by vapored odorant. The odorant (violet) is diluted at the desired concentration in mineral oil (**A**). The solution is then plated into a new 96-well plate, which is placed into the luminometer chamber for 5 min to equilibrate the volume with vapored odorant before monitoring the transfected 96-well plate (**B**). The odorant solution is pipetted into each space between the wells of the transfected 96-well plate (see zoom). The plate is then read for 20 cycles in the luminometer chamber equilibrated vapor odorant (**C**).

Figure 3: Example of normalization that can be performed after data recording. (A) An empty

vector (negative) control is inserted in the transfection plan to be able to identify any potential non-OR specific odor activations of cells. It also provides information on the background luminescence of the plate. **(B**) Each OR response is then normalized by dividing the emission value of each well by the average value of the control vector in each plate. The luminescence values of each OR are then averaged along the measurement cycles. (**C**) OR responses can also then be normalized to their basal activity by further dividing each cycle value by the average value of the 1st cycle of measurement (t = 0 s). (**D**) The AUC can be calculated by summing the emission values of each measurement cycle. For B, C and D, error bars represent the standard error of the mean (SEM, n = 3).

Figure 4. Example of dose dependent responses obtained with the method. (A) The response of Olfr1377 to acetophenone is recorded for five different dilutions in mineral oil (10^{0}, 10^{-2}, 10^{-4}, 10^{-6}, 10^{-8}), and without odorant (0), and normalized following the normalization protocol shown in **Figure 3**. **(B)** The data during the measurement cycles is translated into an AUC value for each dilution. This figure has been modified from Kida et al.[32]. This figure is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0). Error bars represent the standard error of the mean (SEM, n = 3).

Table 1: Mix for transfection. Quantities of plasmids (Glosensor protein, RTP1S and OR) to add to MEM to transfect to one 96-well plate.

DISCUSSION:

The perception of odor is fundamentally dependent on the activation of ORs. Consequently, understanding of their functionality is required to crack the complex mechanisms that the brain use to perceive its volatile chemical environment. However, the understanding of this process has been hampered by the difficulties in establishing a robust method to screen the OR repertoire for functionality against odorants in vitro. Cell surface and heterologous expression of ORs has been partially solved by the creation of tagged receptors[13,19] and by the discovery and optimization of the receptor-transporting proteins (RTPs) expressed in OSNs[22,23]. The first screening studies then appeared, bringing new insights to our understanding of OR function such as their odorant recognition pattern[6,7,26,33], activation mechanism[34,35], theoretical tridimensional structure[36,37], evolution[38,39], odor space[40-42], and implications in odor detection[43-46]. We believe that improving the in vitro methods could boost the deciphering of odor coding. As such, we here developed a new functional assay to allow the monitoring of OR activation by vaporized odorant molecules.

The success of this method depends on several critical steps. Although improved in the recent years, heterologous expression of some ORs remains difficult, which may influence OR responsiveness to odorant. The expression of ORs at the cell membrane can be evaluated in a parallel experiment using flow cytometry[19,24]. Notice that low levels of surface expression can still present robust responses in heterologous cell systems[35]. Another critical point is to avoid odorant contamination. Given the sensitivity of this assay, odorant molecules from any perfume, food, or previous assay can pollute the experiment by inducing uncontrolled OR responses. This is why we advise to vacuum the chamber of the luminometer for at least 2 h, preferably

overnight, before performing an assay with a different odorant. It is also important to consider a potential cytotoxicity of the odorant used in the experiment. A potential decrease of the response of the OR during the 30 min monitoring can show that the odorant itself has a negative effect on the cell health. The odorant cytotoxicity can be evaluated by performing a cell viability assay after exposing the cells to the odorant. To mitigate this problem, it is possible to consider only the first 10 min of the recording time for the analysis of data, cropping the end. We noticed that odorant toxicity mainly occurs when the odorant is tested pure or at very high concentrations. The sensitivity of our assay allows the detection of odorant diluted in mineral oil. The optimal concentration to elicit maximal response varies from one odorant to another, but we observed that a 1% dilution is enough to elicit a saturation of an OR response[32]. However, some odorant molecules can possess low vapor pressure (and therefore low volatility) and may need some adjustments to be made to the presented protocol. The incubation time of the odorant in the luminometer chamber here is set to 5 min. We assumed that this amount of time is sufficient to equilibrate the chamber with odorant volatile molecules, but low volatility odorants may require longer incubation times.

Apart from these critical points, this method brings many new possibilities to exploring the structure-function relationships of odorant-OR interactions. The real-time monitoring aspect of this method also allows for the understanding of the kinetics of events that occur during an odor perception. As an example, we used the protocol to explore the functionality of a metabolite enzyme, the carboxyl esterase 1d (Ces1d), found to be expressed in the olfactory mucosa of mammals[47]. This enzyme is known to convert esters to carboxylic acid and alcohol[48]. The co-transfection of Ces1d showed a modulation of in vitro OR responses to ester compounds,[32] demonstrating that this new protocol is efficient in exploring the importance of metabolic enzymes in odorant detection. Furthermore, using this platform to investigate odorant mixtures, and the way odors are presented in settings that are more natural, will enable future study in understanding more complex odorant interactions. Finally, detection of odorant molecules by ORs is also of high interest in the development of an odor sensor. Having shown that our system can detect odorant molecules presented in a vapor phase, this method is a first step in the development process of a miniaturized biosensor.

ACKNOWLEDGMENTS:

This work was supported by grants from NIH (DC014423 and DC016224) and the Defense Advanced Research Project Agency RealNose Project. YF stayed at Duke University with financial support from JSPS Program for Advancing Strategic International Networks to Accelerate the Circulation of Talented Researchers (R2801). We thank Sahar Kaleem for editing of the manuscript.

DISCLOSURES:

Y.F., H. K and H.M. filed a patent application relevant to this work on 27 October 2016.

REFERENCES:

1 Buck, L., Axel, R. A novel multigene family may encode odorant receptors: a molecular basis for odor recognition. *Cell.* **65** (1), 175-187 (1991).

2 Serizawa, S., Miyamichi, K., Sakano, H. One neuron–one receptor rule in the mouse olfactory system. *Trends in Genetics.* **20** (12), 648-653 (2004).
3 Malnic, B., Hirono, J., Sato, T., Buck, L. B. Combinatorial receptor codes for odors. *Cell.* **96** (5), 713-723 (1999).
4 Hallem, E. A., Carlson, J. R. Coding of odors by a receptor repertoire. *Cell.* **125** (1), 143-160 (2006).
5 Peterlin, Z., Firestein, S., Rogers, M. E. The state of the art of odorant receptor deorphanization: a report from the orphanage. *The Journal of General Physiology.* **143** (5), 527-542 (2014).
6 Saito, H., Chi, Q., Zhuang, H., Matsunami, H., Mainland, J. D. Odor coding by a Mammalian receptor repertoire. *Science Signal.* **2** (60), ra9-ra9 (2009).
7 Geithe, C., Noe, F., Kreissl, J., Krautwurst, D. The broadly tuned odorant receptor OR1A1 is highly selective for 3-methyl-2, 4-nonanedione, a key food odorant in aged wines, tea, and other foods. *Chemical Senses.* **42** (3), 181-193 (2017).
8 Nishizumi, H., Sakano, H. Decoding and deorphanizing an olfactory map. *Nature Neuroscience.* **18** (10), 1432 (2015).
9 Wetzel, C. H. et al. Functional expression and characterization of a Drosophila odorant receptor in a heterologous cell system. *Proceedings of the National Academy of Sciences.* **98** (16), 9377-9380 (2001).
10 Touhara, K. et al. Functional identification and reconstitution of an odorant receptor in single olfactory neurons. *Proceedings of the National Academy of Sciences.* **96** (7), 4040-4045 (1999).
11 Levasseur, G. et al. Ligand‐specific dose‐response of heterologously expressed olfactory receptors. *European Journal Of Biochemistry.* **270** (13), 2905-2912 (2003).
12 Zhao, H. et al. Functional expression of a mammalian odorant receptor. *Science.* **279** (5348), 237-242 (1998).
13 Krautwurst, D., Yau, K.-W., Reed, R. R. Identification of ligands for olfactory receptors by functional expression of a receptor library. *Cell.* **95** (7), 917-926 (1998).
14 Wetzel, C. H. et al. Specificity and Sensitivity of a Human Olfactory Receptor Functionally Expressed in Human Embryonic Kidney 293 Cells andXenopus Laevis Oocytes. *Journal of Neuroscience.* **19** (17), 7426-7433 (1999).
15 Kajiya, K. et al. Molecular bases of odor discrimination: reconstitution of olfactory receptors that recognize overlapping sets of odorants. *Journal of Neuroscience.* **21** (16), 6018-6025 (2001).
16 Jiang, Y. et al. Molecular profiling of activated olfactory neurons identifies odorant receptors for odors in vivo. *Nature Neuroscience.* **18** (10), 1446 (2015).
17 Von Der Weid, B. et al. Large-scale transcriptional profiling of chemosensory neurons identifies receptor-ligand pairs in vivo. *Nature Neuroscience.* **18** (10), 1455 (2015).
18 Geithe, C., Andersen, G., Malki, A., Krautwurst, D. A butter aroma recombinate activates human class-I odorant receptors. *Journal of Agricultural and Food Chemistry.* **63** (43), 9410-9420 (2015).
19 Noe, F. et al. IL-6–HaloTag® enables live-cell plasma membrane staining, flow cytometry, functional expression, and de-orphaning of recombinant odorant receptors. *Journal of Biological Methods.* **4** (4), e81 (2017).

20 Sanz, G., Schlegel, C., Pernollet, J.-C., Briand, L. Comparison of odorant specificity of two human olfactory receptors from different phylogenetic classes and evidence for antagonism. *Chemical Senses.* **30** (1), 69-80 (2005).
21 Shepard, B. D., Natarajan, N., Protzko, R. J., Acres, O. W., Pluznick, J. L. A cleavable N-terminal signal peptide promotes widespread olfactory receptor surface expression in HEK293T cells. *PLoS One.* **8** (7), e68758 (2013).
22 Saito, H., Kubota, M., Roberts, R. W., Chi, Q., Matsunami, H. RTP family members induce functional expression of mammalian odorant receptors. *Cell.* **119** (5), 679-691 (2004).
23 Wu, L., Pan, Y., Chen, G.-Q., Matsunami, H., Zhuang, H. Receptor-Transporting Protein 1 Short (RTP1S) Mediates the Translocation and Activation of Odorant Receptors by Acting through Multiple Steps. *Journal of Biological Chemistry.* jbc. M112. 345884 (2012).
24 Zhuang, H., Matsunami, H. Evaluating cell-surface expression and measuring activation of mammalian odorant receptors in heterologous cells. *Nature Protocols.* **3** (9), 1402 (2008).
25 Zhang, Y., Pan, Y., Matsunami, H., Zhuang, H. Live-cell Measurement of Odorant Receptor Activation Using a Real-time cAMP Assay. *Journal of Visualized Experiments.* (128), e55831-e55831 (2017).
26 Li, S. et al. Smelling sulfur: Copper and silver regulate the response of human odorant receptor OR2T11 to low-molecular-weight thiols. *Journal of the American Chemical Society.* **138** (40), 13281-13288 (2016).
27 Ahmed, L. et al. Molecular mechanism of activation of human musk receptors OR5AN1 and OR1A1 by (R)-muscone and diverse other musk-smelling compounds. *Proceedings of the National Academy of Sciences.* **115** (17), E3950-E3958 (2018).
28 Duan, X. et al. Crucial role of copper in detection of metal-coordinating odorants. *Proceedings of the National Academy of Sciences.* **109** (9), 3492-3497 (2012).
29 Sekharan, S. et al. QM/MM model of the mouse olfactory receptor MOR244-3 validated by site-directed mutagenesis experiments. *Biophysical journal.* **107** (5), L5-L8 (2014).
30 Liu, M. T. et al. Carbon chain shape selectivity by the mouse olfactory receptor OR-I7. *Organic & Biomolecular Chemistry.* **16** (14), 2541-2548 (2018).
31 Li, Y. et al. Aldehyde Recognition and Discrimination by Mammalian Odorant Receptors via Functional Group-Specific Hydration Chemistry. *ACS Chemical Biology.* **9** (11), 2563-2571 (2014).
32 Kida, H. et al. Vapor detection and discrimination with a panel of odorant receptors. *Nature Communications.* **9** (1), 4556 (2018).
33 Yu, Y. et al. Responsiveness of G protein-coupled odorant receptors is partially attributed to the activation mechanism. *Proceedings of the National Academy of Sciences.* **112** (48), 14966-14971 (2015).
34 de March, C. A. et al. Conserved residues control Activation of mammalian G protein-coupled odorant receptors. *Journal of the American Chemical Society.* **137** (26), 8611-8616 (2015).
35 de March, C. A. et al. Odorant receptor 7D4 activation dynamics. *Angewandte Chemie.* **130** (17), 4644-4648 (2018).
36 Kim, S.-K., Goddard, W. A. Predicted 3D structures of olfactory receptors with details of odorant binding to OR1G1. *Journal of Computer-Aided Molecular Design.* **28** (12), 1175-1190 (2014).

37 de March, C. A., Kim, S. K., Antonczak, S., Goddard III, W. A., Golebiowski, J. G protein‐coupled odorant receptors: From sequence to structure. *Protein Science.* **24** (9), 1543-1548 (2015).
38 Adipietro, K. A., Mainland, J. D., Matsunami, H. Functional evolution of mammalian odorant receptors. *PLoS Genetics.* **8** (7), e1002821 (2012).
39 Mainland, J. D. et al. The missense of smell: functional variability in the human odorant receptor repertoire. *Nature Neuroscience.* **17** (1), 114 (2014).
40 Meister, M. On the dimensionality of odor space. *Elife.* **4** e07865 (2015).
41 Bushdid, C., Magnasco, M. O., Vosshall, L. B., Keller, A. Humans can discriminate more than 1 trillion olfactory stimuli. *Science.* **343** (6177), 1370-1372 (2014).
42 Gerkin, R. C., Castro, J. B. The number of olfactory stimuli that humans can discriminate is still unknown. *Elife.* **4** e08127 (2015).
43 Shirasu, M. et al. Olfactory receptor and neural pathway responsible for highly selective sensing of musk odors. *Neuron.* **81** (1), 165-178 (2014).
44 Keller, A., Zhuang, H., Chi, Q., Vosshall, L. B., Matsunami, H. Genetic variation in a human odorant receptor alters odour perception. *Nature.* **449** (7161), 468 (2007).
45 McRae, J. F. et al. Genetic variation in the odorant receptor OR2J3 is associated with the ability to detect the “grassy” smelling odor, cis-3-hexen-1-ol. *Chemical Senses.* **37** (7), 585-593 (2012).
46 de March, C. A., Ryu, S., Sicard, G., Moon, C., Golebiowski, J. Structure–odour relationships reviewed in the postgenomic era. *Flavour and Fragrance Journal.* **30** (5), 342-361 (2015).
47 Olson, M. J., Martin, J. L., LaRosa, A. C., Brady, A. N., Pohl, L. R. Immunohistochemical localization of carboxylesterase in the nasal mucosa of rats. *Journal of Histochemistry & Cytochemistry.* **41** (2), 307-311 (1993).
48 Nagashima, A., Touhara, K. Enzymatic conversion of odorants in nasal mucus affects olfactory glomerular activation patterns and odor perception. *Journal of Neuroscience.* **30** (48), 16391-16398 (2010).

Figure 1



Figure 2



Figure 3



Figure 4



Table 1

	Per 96-well plate
MEM	500 µL
pGlosensor	10 ng
RTP1S	5 ng
OR	75 ng

Table of Materials

Click here to access/download;Table of Materials;Glovap_Materials.xlsx

Name of Material/ Equipment	Company	Catalog Number
0.05 % trypsin-EDTA	Gibco	25300-054
100 mm cell culture dish	BD Falcon	353003
15 mL tube	BD Falcon	352099
96-well plate	Corning	3843
Amphotericin	Gibco	15290-018
centrifuge machine	Jouan	C312
Class II Type A/B3 fumehood	NUAIRE	NU-407-500
FBS	Gibco	16000-044
GloSensor cAMP Reagent	Promega	E1290
Incubator 37 °C; 5 % CO_2	Fisher Scientific	11-676-604
Lipofectamine 2000 reagent	Invitrogen	11668-019
Luminometer POLARstar OPTIMA	BMG LABTECH	discontinued
Mineral oil	Sigma	M8410
Minimum Essential Medium (MEM)	Corning cellgro	10-010-CV
Penicillin/Streptomycin	Sigma Aldrich	P4333
pGlosensor	Promega	E2301
phase contrast microscope	Leica	090-131.001
RTP1S	H. Matsunami lab	-

Comments/Description
0.05% Trypsin - EDTA (1x), phenol red - store at 4°C
100 mm x 20 mm cell culture dish
17 mm x 120 mm conical tubes
96 well, with LE lid white with clear bottom Poly-D-lysine coated Polystyrene
Amphotericin B 250 µg/mL - store at 4°C
Centrifuge machine with swinging bucket rotor for 15 mL
fumehood for cell culturing
Fetal Bovine Serum - store at -20°C
GloSensor cAMP Reagent luminescent protein substrate - store at -20°C
Incubator for cell culturing
Lipofectamine 2000 Reagent 1mg/ml transfection reagent - store at 4°C
96 well plate reader for luminescence
Solvent for odorants - store at room temperature
Minimum Essential Medium Eagle with Earle's salts & L-glutamine - store at 4°C
Penicillin-Streptomycin solution stabilized with 10,000 U of penicillin and 10 mg streptomycin - store at -20°C
pGloSensor-22F cAMP luminescent protein plasmid - store at 4°C
phase contrast microscope with x4, x10, x20 objectives
100 ng/µL plasmid - store at 4°C

jove JOURNAL OF VISUALIZED EXPERIMENTS
1 Alewife Center #200
Cambridge, MA 02140
tel. 617.945.9051
www.jove.com

ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article: Real-time in vitro monitoring of odorant receptor activation by odorant in vapor phase

Author(s): Claire A. de March, Yosuke Fukutani, Aashutosh Vihani, Hitoshi Kida, Hiroaki Matsunami

Item 1 (check one box): The Author elects to have the Materials be made available (as described at http://www.jove.com/author) via: ☑ Standard Access ☐ Open Access

Item 2 (check one box):

☑ The Author is NOT a United States government employee.

☐ The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.

☐ The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

ARTICLE AND VIDEO LICENSE AGREEMENT

1. Defined Terms. As used in this Article and Video License Agreement, the following terms shall have the following meanings: "**Agreement**" means this Article and Video License Agreement; "**Article**" means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; "**Author**" means the author who is a signatory to this Agreement; "**Collective Work**" means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; "**CRC License**" means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode; "**Derivative Work**" means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; "**Institution**" means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; "**JoVE**" means MyJove Corporation, a Massachusetts corporation and the publisher of *The Journal of Visualized Experiments;* "**Materials**" means the Article and / or the Video; "**Parties**" means the Author and JoVE; "**Video**" means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion of the Article, and in which the Author may or may not appear.

2. Background. The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. Grant of Rights in Article. In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to **Sections 4** and **7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the "Open Access" box has been checked in **Item 1** above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

4. Retention of Rights in Article. Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. Grant of Rights in Video – Standard Access. This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. Grant of Rights in Video – Open Access. This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this Section 6 is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. Government Employees. If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum rights permitted under such statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. Likeness, Privacy, Personality. The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

9. Author Warranties. The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

10. JoVE Discretion. If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have

full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

11. Indemnification. The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in *JoVE* or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

12. Fees. To cover the cost incurred for publication, JoVE must receive payment before production and publication the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

13. Transfer, Governing Law. This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to me one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement required per submission.

CORRESPONDING AUTHOR:

Name:	Claire A. de March
Department:	Molecular Genetics and Microbiology
Institution:	Duke University
Article Title:	Real-time in vitro monitoring of odorant receptor activation by odorant in vapor phase
Signature:	 Date: 11.19.18

Please submit a signed and dated copy of this license by one of the following three methods:

1) Upload a scanned copy of the document as a pfd on the JoVE submission site;
2) Fax the document to +1.866.381.2236;
3) Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02139

For questions, please email submissions@jove.com or call +1.617.945.9051

Dear editor,

Please find our response to the referees' comments. We thanks the referees for their interesting comments. We have taken into account all their remarks. 7 citations were inserted in our references and a proper description of some previous work was added in the introduction. All materials used in the protocol were described in the Table of materials and several sections of the protocol were clarified. We modified each figure to address the editorial and referees' comments. A paragraph comparing liquid and vapor stimulations was added to the representative results as well as a comparison of our assay results with those of the previous work of Sanz et al. 2005. Finally, an eventual optimization of the saturation time was proposed in the discussion.
All changes are highlighted in yellow and are commented in the following referees' point-by-point response. The Rights and permissions policy from Nature Communications is attached to the submission for the editorial concerns on figure 4.

Hiroaki Matsunami and Claire de March

Editorial comments:
Changes to be made by the author(s) regarding the manuscript:

1. Please take this opportunity to thoroughly proofread the manuscript to ensure that there are no spelling or grammar issues.

R: We thoroughly proofread the manuscript and corrected typos.

2. Please obtain explicit copyright permission to reuse any figures from a previous publication. Explicit permission can be expressed in the form of a letter from the editor or a link to the editorial policy that allows re-prints. Please upload this information as a .doc or .docx file to your Editorial Manager account. The Figure must be cited appropriately in the Figure Legend, i.e. "This figure has been modified from [citation]."

R: We used raw data from the supporting information of Kida et al. 2018 published in Nature Communication (Figure S5 and S11). The graphic chart has been changed and data does not look like those from the original publication. Furthermore, the editorial policy of Nature communication allowed reproduction of any material as long as the original authors, paper and a link to the creative Commons License is included.
"Figure 4B. The data during the measurement cycles is translated into an AUC value for each dilution. This figure has been modified from Kida et al.[32]. This figure is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0). Error bars represent the standard error of the mean (SEM, n = 3)."

3. Please remove the embedded figures/tables from the manuscript. All figures should be uploaded separately to your Editorial Manager account.

R: Done

4. Figure 2 and Table 1: Please include a space between all numerical values and their corresponding units (25 µL, 5 min, 500 µL, 10 ng, 5 ng).

R: Done

5. Figure 3 and Figure 4: Please change the time unit "sec" to "s". Please change "time[sec]" to "Time [s]" in panels B and C of Figure 3 and in panel A of Figure 4. Please define error bars in the figure legend.

R: Done

6. Table of Materials: Please use SI abbreviations for all units (L, mL, µL) and include a space between all numerical values and their corresponding units (15 mL, 37 °C, etc.). Please remove trademark (™) and registered (®) symbols. Please sort the items in alphabetical order according to the name of material/equipment.

R: Done

7. Please define all abbreviations before use.

R: Done

8. Please include a space between all numerical values and their corresponding units: 15 mL, 37 °C, 60 s; etc.

R: Done

9. JoVE cannot publish manuscripts containing commercial language. This includes trademark symbols (™), registered symbols (®), and company names before an instrument or reagent. Please remove all commercial language from your manuscript and use generic terms instead. All commercial products should be sufficiently referenced in the Table of Materials and Reagents. You may use the generic term followed by "(see table of materials)" to draw the readers' attention to specific commercial names. Examples of commercial sounding language in your manuscript are: GloSensor, lipofectamine, etc.

R: Done

10. 2.5: Please convert centrifuge speeds to centrifugal force (x g) instead of revolutions per minute (rpm).

R: Done

11. 1.3: Please describe how to divide cells at a 20% ratio.

R: Done

12. 2.3: Please specify the reaction temperature.

R: Done

13. 4.6, 5.2: Please specify the incubation temperature.

R: Done

14. Please combine some of the shorter Protocol steps so that individual steps contain 2-3 actions and maximum of 4 sentences per step.

R: Done

15. Please include single-line spaces between all paragraphs, headings, steps, etc.

R: Done

Reviewers' comments:

Reviewer #1: Manuscript Summary:
The article describes in detail a method for high throughput screening for odorant receptor ligands that was recently published (Kida et al, 2018, Nat Commun., 2018). This method is a modified version of a previous one, which used a heterologous expression system (Hana3A cells transfected with expression vectors for odorant receptors, other accessory factors and a CRE-luciferase reporter) in 96 well plates, to screen a large number of odorants and odorant receptors. This new method uses now the Glosensor assay instead of the CRE-luciferase reporter, and therefore allows for real-time monitoring of odorant receptor activation. In addition, to better reflect the in vivo odorant responses in the nose, the cells are now induced by odorants in vapor phase, instead of odorants that are diluted into the cell media. The detailed protocol should be very useful for researches in the olfactory field.

Major Concerns:
I have the following suggestions to make it clearer:

1- Figure 1: the way that RTP1S is depicted in this figure, makes the reader think that there is no direct interaction between RTPs1 and the OR. Is this supported by previous experiments? Otherwise, the figure should be corrected.

R: We corrected the figure by placing RTP1S close by the OR and highlighted it in gray since it has been shown that OR and RTP1S can be immunoprecipitated, demonstrating that these two proteins can interact with each other. (Wu, Lifang, et al. "Receptor-Transporting Protein 1 Short (RTP1S) Mediates the Translocation and Activation of Odorant Receptors by Acting through Multiple Steps." Journal of Biological Chemistry (2012): jbc-M112.)

2- Line 116. The authors mention 'A number of independent groups have utilized various approaches'. And reference only two groups. More references or reviews on heterologous expression of OR genes could be cyted here.

R: We added twelve citations studying OR function in *in vitro* systems from various laboratory[2-13] »
. We revised the text as follows: “A number of independent groups have utilized various approaches.[5-12, 14, 18-20]»

3- Line 156: indicate the concentration of EDTA in this solution.

R: We added the concentration of EDTA in the protocol and the corresponding commercial product on the Table of materials.

“1.4 Aspire PBS and add 3 mL of 0.05 % trypsin-ethylene diamine tetraacetic acid (EDTA, 0.48 mM). Let act for approximately 1 min, until the cells dissociate from the plate

0.05 % trypsin-EDTA	Gibco	25300-054	0.05% Trypsin - EDTA (1x), phenol red - store at 4°C

“

4- Line 167: explain this better: for one 96 well plate should dilute the 600 micro liter in 4,8 ml, and pipet from this 50 /well?

R: The total final volume for one plate should be 6 mL, so if starting with a 100 % confluence plate, we add 500 µL of the 5 mL of resuspended cell solution in 5.5 mL of fresh M10PSF. We added an explanation and indicated how to realize one 96-well plate.

“2.5 Depending on the number of plates to be transfected, transfer an appropriate amount of cells in a reservoir with the proper corresponding volume of M10PSF. One 96-well plate should be plated with 1/10 of a 100 % confluent 100 mm dish (approximately 1.1 x 10^6 cells) diluted in M10PSF to reach a total volume of 6 mL. For one 96-well plate starting with a 100 % confluence 100 mm dish, add 500 µL from the 5 mL of resuspended cells to 5.5 mL of fresh M10PSF. Mix the cells and M10PSF without generating air bubbles.”

5- Table 1: OR plasmids should be included in table 1. (including the amount in ng to be used).

R: We added the OR plasmid amount in Table 1

	Per 96-well plate
MEM	500 µL
pGlosensor	10 ng
RTP1S	5 ng
OR	75 ng

« Table1: Mix for transfection.

Quantities of plasmids (Glosensor protein, RTP1S and OR) to add to MEM to transfect to one 96-well plate.”

6- Line 186: Explain in details how to vacum the chamber.

R: We added a reference to the chamber vacuum section step (6) and provided a more detailed protocol for removing odors from the luminometer chamber. We revised the text as follows:
“3.4 Replace the M10PSF contained into the previously platted 96-well plate by 50 µL of the final transfection media. Incubate in an incubator set to 37 °C and 5 % CO_2 and vacuum the chamber of the luminometer overnight following the procedure described in step 6.
6. Remove remaining odorant inside the luminometer
6.1 Open the door of the luminometer. Insert tube connected to the vacuum pump.
6.2 Vacuum odorants in the reading chamber extensively (at least 2 hours, preferably overnight) between two odorants to avoid cross contamination of odor volatiles from one experiment to another. Replace with fresh air by sending compressed air during 5 min before incubating the next odorant.”

7- Line 197: Reagent solution included in the glosensor kit? Where does it come from?

R: The Glosensor cAMP reagent solution is from the Glosensor kit (catalog number E1290) from Promega. The reference to the Promega kit is mentioned in the Table of materials. We now refer to this table in the protocol step.
“4.2 Dilute 75 µL of the Glosensor cAMP reagent (see **Table of Materials)** solution to 2.75 mL of the stimulation solution. Remove the transfection medium from the 96-well plate and wash the cells by adding 50 µL of fresh stimulation solution to each well

GloSensor cAMP Reagent	Promega	E1290	GloSensor cAMP Reagent luminescent protein substrate - store at -20°C

“

8- Line 198: what is considered to be an odor free environment? Give one example.

R: We use a clean empty drawer far from any odorant sources in our lab. We give now an example of odor free environment in this protocol section. We revised the text as follows:
“4.3 Remove the stimulation solution and add 25 µL of Glosensor cAMP reagent solution prepared in 4.2 to each well. Incubate the 96-well plate at room temperature in a dark and odor-free environment (for example a clean empty drawer far away from chemicals or any odorant source) for 2 hours.”

9- Line 206: odorants with low vapor pressures could require longer times?

R: We thanks the reviewer for this comment. The incubation time is a parameter we have not fully optimized. We added a comment in the discussion as follows.
“The optimal concentration to elicit maximal response varies from one odorant to another, but we observed that a 1 % dilution is enough to elicit a saturation of an OR response.[32] However, some odorant molecules can possess low vapor pressure (and therefore low volatility) and may need some adjustments to be made to the presented protocol. The incubation time of the odorant in the luminometer chamber here is set to 5 min. We assumed that this amount of time is sufficient to equilibrate the chamber with odorant volatile molecules, but low volatility odorants may require longer incubation times.”

10- Line 209: what exactly does cycle here mean? What kind of luminometer was used? Are there other options? How to set the luminometer?

R: By cycle we mean one luminescence recording of all wells of the 96-well plate. This cycle is set at 90 s with 0.7 s of interval between two cycles. The luminescence recording is done on a POLARstar OPTIMA from BMG LABTECH. The luminometer description has been added in the Table of materials. The set-up of the luminometer reading has been added in the protocol.
“5.2 Set the luminometer to record the luminescence with 0 s of delay during 20 cycles of plate measurement of 90 s with 0.7 s of interval between cycles.

Luminometer POLARstar OPTIMA	BMG LABTECH	discontinued	96 well plate reader for luminescence

“

11- Line 214 and 216: vacuum or wait for how long, between testing different odorants? 6.4 'Replace with fresh air before next measurement.' How exactly?

R: We vacuum the chamber at least 2 h between each measurement, preferably overnight. After the vacuum time, we replace the air in the chamber with fresh air by injecting compressed air for 5 min before saturating the chamber with an odorant. We clarified this step in the protocol.
“6. Remove remaining odorant inside the luminometer
6.1 Open the door of the luminometer. Insert tube connected to the vacuum pump.
6.2 Vacuum odorants in the reading chamber extensively (at least 2 hours, preferably overnight) between two odorants to avoid cross contamination of odor volatiles from one experiment to another. Replace with fresh air by sending compressed air during 5 min before incubating the next odorant.”

Minor Concerns:

Text should be revised. There are many errors, for example:
Line 95: 'to interact of their volatile'
R: Done
Line 100: a word is missing here: rhodopsin-like class (class A).

R: Done
Line 102: pattern of activated ORs.
R: Done
Line 110: the word realized is incorrectly used here.
R: Done
Line 131: where odorant molecules reach the olfactory epithelium.
R: Done
Line 163: Depending on the number
R: Done
Line 211: remaining
R: Done
Line 213: vacuum pump?
R: Done
Line 231: to also normalize their response to this parameter (Figure 3C)
R: Done
Line 241: possessing a higher vapor pressure is more volatile
R: Done
Line 262: luminescence that is recorded
R: Done
Line 269: pipetted in each space… The plate is then read
R: Done
Line 278: dividing each cycle value by the
R: Done
Line 314: assay after exposure of the cells to the odorant
R: Done
Line 324: the protocol to explore the functionality
R: Done
Line 325: This enzyme is known
R: Done
Figure 3 and legend: control vector (and not vector control)
R: Done

Reviewer #2: Authors report a new protocol, based on a previous study published in Nat.Com. (2018, ref.24), to monitor in real time olfactory receptor activation in vitro. The experimental procedure explain how to measure OR response to odorants in vapor phase while, in conventional in vitro protocol, odorants are dissolved in liquid phase. In short, authors have acknowledged expertise in cell-based functional assays of ORs and the innovative nature of the experimental protocol deserves to be published in JoVE with the following minor revisions :

- l.204-209 : Reading the '5.Odorant stimulation' part, I understand that, in a first step, authors add the odorants in liquid phase directly into each well (l.205-206, Fig.2B). Then, in a second step, they add odorants between the wells (l.208-209, Fig.2C). Does it means that they record 2 types of OR activation (liquid and vapor phase) ? Do they use the conventional in vitro assay (first step) as a control? Please clarify the text.

R: The first step is only to saturate the luminometer chamber in volatile odorant. For this propose, we use a plate without the cells and no luminescence recording is done during this first step. The second step is the luminescence recording. We inject odorant in the space between each well to keep the air in equilibrium with the tested odor during the 30 min of measurement. We clarified the distinction between the saturation of the luminometer chamber and the OR activation recording by luminescence by modifying the protocol text and Figure 2.
"5. Odorant stimulation
[Insert Figure 2]

5.1 First, equilibrate the luminometer chamber with volatile odorant molecules. Dilute the odorant to the desired concentration in 10 mL of mineral oil (**Figure 2A**). Before the end of the Glosensor cAMP reagent incubation time, add 25 µL of the odorant solution in a new 96-well plate (not the one containing the cells). Incubate this odorant plate at room temperature in the luminometer chamber for 5 min (**Figure 2B**) (no luminometer recording is required here).
5.2 Set the luminometer to record the luminescence with 0 s of delay during 20 cycles of plate measurement of 90 s with 0.7 s of interval between cycles.
5.3 Right before reading the plate, remove the odorant plate from the chamber. Add 25 µL of odorant between the wells of the 96-well plate containing the cells (do not add the odorant in the wells containing the cells) and quickly start the luminescence measurement of all wells for 20 cycles within 30 min (**Figure 2C**)."

- Author mentioned that it's possible to determine EC50 of OR using their new techniques (l.247, Fig.4B). Can you give a bit more details? Are EC50 determined from 'in real time/vapor phase' in vitro assays comparable to conventional ones?

R: We can obtain EC50 by recording OR activation upon a series of odorant dilution in mineral oil. The EC50 obtained is different from direct liquid stimulation since it takes into account the odorant molecules kinetic of diffusion in air and in the media, its vapor pressure, its solubility in the media and its interaction with the OR. We added a discussion about the differences between conventional EC50 and the EC50 obtained with our method in the representative results. We also compare our results with those from Sanz et al.
"Further, since the real concentration of odorant molecules in the cell media is not known, the EC50s obtained by this method are not necessarily comparable to those obtained by liquid stimulation. The EC50 values determined by our method take into account the odorant volatility, the kinetics of odorant dissolution into the medium, the odorant's solubility, and the affinity between the odorant and the OR, which are closer to the natural perception of odor. For our example of Olfr1377 stimulation by acetophenone, the EC50 value from our vapor dose-response is 161 µM (0.001874 %), which is around 50 fold higher than the liquid stimulation (3.28 µM from Saito et al.[6]). This difference between liquid and vapor stimulations was also reported by Sanz et al.[20] in their vapor stimulation assay where vapor stimulation gave 100 to 1000 fold lower EC50 values than the liquid stimulation."

- few typos :
(l.84) in the abstract, please explain what ID means.
R: We meant ID as an identification card which is specific to each odor but we understand the confusion and decided to remove this reference to an ID
(l.95) 'interact with' and not 'interact of'.
R: Done
(l.114) '...in functionally expressing ...'
R: Done

Reviewer #3: Manuscript Summary:

In their manuscript "Real-time in vitro monitoring of odorant receptor activation by odorant in vapor phase" (JoVE59446), de March et al. describe a method that allows real-time monitoring of odorant receptor activation stimulated with vapor odorants. The authors used the pGloSensorTM assay for the in vitro measurement of odorant receptor activation. The authors claim that presenting odorants in the vapor phase is more similar to a natural odor perception than perfusion of odorant receptor-expressing test cells with odorants dissolved in physiological buffer solution.

Major Concerns:

General comments:
Overall, this methods article is well written and easy to follow, and appears technically sound. In general, however, the notion that volatile compounds will activate buffer-submerged, odorant receptor-expressing test cells, if just their dose in the vapor phase is high enough, does not come as a surprise. In fact, the two experimental techniques on which this manuscript relies have been published many years ago:
For the odorant receptor activation stimulated with vapor odorants, see G. Sanz et al., Comparison of odorant specificity of two human olfactory receptors from different phylogenetic classes and evidence for antagonism. Chem Senses, 2005. 30(1): p. 69-80.
Then, 13 years ago, Sanz et al. termed their assay "volatile-odorant functional assay" (VOFA).
The pGloSensorTM assay for the in vitro measurement of odorant receptor activation has been published first in detail in 2015 by C. Geithe et al., Butter Aroma Recombinate Activates Human Class-I Odorant Receptors. J Agric Food Chem, 2015. 63(43): p. 9410-20, and later on by F. Noe et al. 2017, JBM.
Interestingly, both papers (Sanz et al., 2005 and Geithe et al. 2015) are not cited, and therefore are also not discussed by the authors in the appropriate context, which is a pity, because, typically, such a discussion helps both the authors and putative future readers of their manuscript.
I therefore believe that it is mandatory to cite both papers, and in the correct context.

R: We are thankful to the reviewer for this comment and fixed our omission. We added a proper citation of those papers in the text. We describe the method used by Sanz et al. to stimulate OR with odorant in vapor phase. We also added a large samples of publications using Glosensor to monitor OR activation since 2012.
"This is very distinct from the physiological conditions where odorant molecules reach the olfactory epithelium in vapor phase and activate ORs by dissolution into the nasal mucosa. To more closely resemble physiologically relevant stimulus exposure, Sanz et al.[20] proposed an assay based on vapor stimulation by applying a drop of odorant solution to hang beneath the inner face of a plastic film placed on the top of cell wells. They recorded the calcium responses by monitoring fluorescence intensity. This method was the first to use air-phase odorant stimulation, but it did not allow a large screening of OR activation.
Here, we developed a new method that enables real-time monitoring of *in vitro* OR activation via vapor phase odorant stimulation by the Glosensor assay (**Figure 1**). This assay has been used previously in the context of liquid odorant stimulation.[18,19,25-31] »

In general, the same question as 13 years ago arises, and needs to be discussed by the authors:
With respect to de-orphaning of hundreds of odorant receptors, what is the benefit of having a rather insensitive, air-water partition coefficient-biased odorant dose, but not odorant concentration (!), application system, which relies on the incubation of OR-expressing test cells for half an hour in high odorant dose-derived head-space vapors?

R: We added a discussion in the present revised version where we compare EC50 obtained by vapor and liquid stimulations. We also compared our results to those from Sanz et al. 2005. We think the Vapor assay may not be suitable for early de-orphanization. pS6 (vapor phase stimulation *in vivo*) and Dual luciferase (liquid phase stimulation *in vitro*) are more suitable for de-orphanization in terms of HTS. However, OR responses using the two methods do not always agree with each other (Jiang et al., 2015). Vapor assay is proposed to help fill the gap.
"Further, since the real concentration of odorant molecules in the cell media is not known, the EC50s obtained by this method are not necessarily comparable to those obtained by liquid stimulation. The EC50 values determined by our method take into account the odorant

volatility, the kinetics of odorant dissolution into the medium, the odorant's solubility, and the affinity between the odorant and the OR, which are closer to the natural perception of odor. For our example of Olfr1377 stimulation by acetophenone, the EC50 value from our vapor dose-response is 161 µM (0.001874 %), which is around 50 fold higher than the liquid stimulation (3.28 µM from Saito et al.[6]). This difference between liquid and vapor stimulations was also reported by Sanz et al.[20] in their vapor stimulation assay where vapor stimulation gave 100 to 1000 fold lower EC50 values than the liquid stimulation."

Here, the authors at least should discuss or point out that their presented method is only suitable to obtain dose-response relationships and not concentration-response relationships like the already known pGloSensorTM assay for ORs published by C. Geithe et al. 2015, and F. Noe et al. 2017).

R: We clarified this point in the representative results by replacing "concentration" by dose or dilution. We also corrected the label of the x-axis of Figure 4B.
"Nevertheless, we can observe a typical dose dependency behavior of Olfr1377, (**Figure 4B**) showing that this method can also be used to determine the EC50 of OR to volatile compound."

Further, the authors should consider giving the appropriate name "pGloSensorTM" instead of using "Glosensor".

R: We follow the editorial policy, "JoVE cannot publish manuscripts containing commercial language. This includes trademark symbols (™)."

The authors should add more details and information for the odorants, salts, reagents and equipment they use during their assay. For example, they do not tell the reader which luminometer they used in their assay setup, and they do not give any information and instruction on preparation or storage of solutions.

R: We improved the Table of materials and reagents by adding the luminometer, fume hood, incubator, microscope, centrifuge machine used and the storage temperature of every solutions.

Specific comments:
Line 154: The authors should make sure, whether they really take 100% confluent cells into their experiments.
R: Done
Line 165: The authors should give the number of cells that typically should be transferred to one 96-well plate, or to one well of a 96-well plate.
R: Done
Line 173: The authors should add that it is necessary to have an empty vector control for each experiment and plate, and a positive control for each plate.
R: Done
Lines 220 - 234: The authors should give more details on their calculations and data analysis.
R: Done
Lines 238 - 248: The authors write correctly "dose dependency" in this section; however, in Figure 4 B they use the term "odorant concentration" of acetophenone, which is incorrect, since this is a dose rather than the actual concentration at the receptor. Further, the authors should consider including a clear protocol on how to examine dose dependency, since one 96-well plate can only be measured with one odorant concentration. Their measurement takes about 35 minutes, and they advise to vacuum the chamber of the luminometer for at least 2 hours between two odorants. So, for example, how is it ensured that one cell passage is used for one "dose dependency" measurement?

R: We changed the label of the x-axis of Figure 4B for "odorant dilution in mineral oil". We consider that vacuum is not necessary if measuring the same odorant at different dilutions. In this case, the dilutions are recorded from the lowest to the highest one after the other. We added a comment in that sense in the representative results section.

"Note that when dose-dependent experiments are performed, we do not vacuum clean the luminometer chamber. However, experiments are always performed from low to high, increasing odorant doses to minimize contaminations."

1 Kida, H. *et al.* Vapor detection and discrimination with a panel of odorant receptors. *Nature Communications.* **9** (1), 4556, (2018).

2 Peterlin, Z., Firestein, S. & Rogers, M. E. The state of the art of odorant receptor deorphanization: a report from the orphanage. *The Journal of general physiology.* **143** (5), 527-542, (2014).

3 Saito, H., Chi, Q., Zhuang, H., Matsunami, H. & Mainland, J. D. Odor coding by a Mammalian receptor repertoire. *Sci. Signal.* **2** (60), ra9-ra9, (2009).

4 Geithe, C., Andersen, G., Malki, A. & Krautwurst, D. A butter aroma recombinate activates human class-I odorant receptors. *Journal of agricultural and food chemistry.* **63** (43), 9410-9420, (2015).

5 Geithe, C., Noe, F., Kreissl, J. & Krautwurst, D. The broadly tuned odorant receptor OR1A1 is highly selective for 3-methyl-2, 4-nonanedione, a key food odorant in aged wines, tea, and other foods. *Chemical senses.* **42** (3), 181-193, (2017).

6 Noe, F. *et al.* IL-6–HaloTag® enables live-cell plasma membrane staining, flow cytometry, functional expression, and de-orphaning of recombinant odorant receptors. *Journal of Biological Methods.* **4** (4), e81, (2017).

7 Nishizumi, H. & Sakano, H. Decoding and deorphanizing an olfactory map. *Nature Neuroscience.* **18** (10), 1432, (2015).

8 Wetzel, C. H. *et al.* Functional expression and characterization of a Drosophila odorant receptor in a heterologous cell system. *Proceedings of the National Academy of Sciences.* **98** (16), 9377-9380, (2001).

9 Wetzel, C. H. *et al.* Specificity and Sensitivity of a Human Olfactory Receptor Functionally Expressed in Human Embryonic Kidney 293 Cells andXenopus Laevis Oocytes. *Journal of Neuroscience.* **19** (17), 7426-7433, (1999).

10 Touhara, K. *et al.* Functional identification and reconstitution of an odorant receptor in single olfactory neurons. *Proceedings of the National Academy of Sciences.* **96** (7), 4040-4045, (1999).

11 Levasseur, G. *et al.* Ligand-specific dose–response of heterologously expressed olfactory receptors. *European journal of biochemistry.* **270** (13), 2905-2912, (2003).

12 Zhao, H. *et al.* Functional expression of a mammalian odorant receptor. *Science.* **279** (5348), 237-242, (1998).

13 Sanz, G., Schlegel, C., Pernollet, J.-C. & Briand, L. Comparison of odorant specificity of two human olfactory receptors from different phylogenetic classes and evidence for antagonism. *Chemical senses.* **30** (1), 69-80, (2005).

Rights and permissions